Storage is the least discussed and most consequential thing that happens to cannabis after it leaves the laboratory, and knowing how to store cannabis properly comes down to four variables.

Moisture: the One That Matters Most

Too dry and the material becomes brittle, terpenes are lost, and the smoke is harsh. Too wet and mold grows.

The target range for cured flower is generally 55–62% relative humidity in the storage container. Two-way humidity control packs hold that range by absorbing or releasing moisture as conditions change, which is why they are standard in commercial packaging.

Moisture content is not water activity

These two measurements get used interchangeably and they are not the same thing.

Moisture content is how much water is present, as a percentage of weight.

Water activity is how much of that water is chemically available — free rather than bound to the material.

Availability, not quantity, is what determines whether microorganisms can grow. Below roughly 0.65 a_w, most molds cannot establish. Above it, they can, and the risk rises quickly.

Two batches with identical moisture content can have different water activity depending on how the water is bound. That is why water activity testing is a better predictor of shelf stability than moisture content, and why it is on the compliance panel in most markets.

For producers, water activity is the single most useful early-warning measurement available. A batch that passes microbial screening with water activity near the upper limit is a batch that may fail later in storage. Treating it as an early indicator rather than a box to tick prevents more microbial failures than any other single practice — the failure pathways are mapped in contaminant testing explained.

Light

Ultraviolet light degrades cannabinoids. THC oxidises to CBN under light exposure, which reduces potency and changes the profile.

Store in opaque containers, or in glass kept in a dark place. Clear jars on a shelf look appealing and are actively harmful to the contents.

An elevated CBN figure alongside depressed THC on a certificate is a reliable signal of light or heat exposure — see cannabinoids explained.

Temperature

Heat accelerates every degradation process: cannabinoid oxidation, terpene evaporation, and — combined with moisture — microbial growth.

Cool and stable is the goal. Room temperature away from heat sources works. What matters as much as the absolute temperature is stability, because fluctuation drives condensation inside containers, and condensation raises water activity exactly where you do not want it.

Refrigeration is generally a poor idea for flower. The temperature swings each time the container comes out cause condensation, and the humidity in a domestic fridge is wrong. Freezing preserves cannabinoids well but makes trichomes brittle, so material handled while frozen loses resin.

Air

Oxygen drives oxidation. An airtight container limits the available oxygen and, just as importantly, limits humidity exchange with the room.

Glass jars with sealing lids are the standard for a reason: they are airtight, non-reactive and do not off-gas. Plastic bags are poor — they are not airtight, they build static that strips trichomes, and some plastics interact with terpenes.

Vacuum sealing is effective for long-term storage of material that will not be opened repeatedly, though it can compress flower.

Ventilation Around Storage

Containers control the immediate environment. The room matters too.

For anyone storing quantity — growers, processors, or patients cultivating at home — a storage area with stagnant humid air is a mold problem waiting to happen. Air movement prevents damp pockets forming, and controlled ventilation keeps ambient humidity stable so containers are not fighting the room.

This applies equally to drying and curing spaces, where most microbial problems actually originate. A drying room with poor airflow produces material that fails microbial screening regardless of how well it was grown. It is also a respiratory issue for anyone working in the space — mold spores in a poorly ventilated room are a hazard to people as well as to product.

Different Products, Different Rules

Concentrates are more temperature-sensitive than flower. Many need refrigeration to hold consistency, and some separate at room temperature. Follow the producer’s guidance — it is usually specific to the formulation.

Edibles follow food rules first. Anything perishable stays perishable regardless of what is infused into it, and cannabinoids degrade alongside everything else.

Tinctures and oils keep well in cool, dark conditions in the original container. Ultraviolet exposure is the main threat.

Vape cartridges should be stored upright to limit leakage, and kept out of heat.

How Long It Actually Lasts

Well-stored cured flower holds up reasonably for six months to a year. Cannabinoids degrade slowly; terpenes go first, which is why old flower smells flat before it tests noticeably weaker.

Badly stored flower can deteriorate in weeks. Warm, bright, humid conditions are the worst combination — and mold can develop without being obviously visible.

If material smells of ammonia, looks or feels damp, shows any white or gray growth, or smells musty, do not use it. A batch that was safe when tested is not necessarily safe now, which is one of the limits discussed in the limits of current testing methods.

The Practical Summary

• Airtight glass, opaque or kept dark
• Humidity control packs holding 55–62% RH
• Cool and stable — avoid fluctuation more than any particular temperature
• No fridge for flower, no plastic bags
• Ventilated storage area, especially at volume
• Buy quantities you will use within a few months

A certificate describes a sample on a date. Everything after that is storage.

The post How to Store Cannabis Properly — and Why Water Activity Matters appeared first on TruMo Analytics.

Understanding what each one is — and particularly the difference between the acidic and neutral forms — makes a potency report considerably easier to read.

What a Cannabinoid Is

Cannabinoids are a family of compounds produced mainly in the trichomes, the resin glands concentrated on cannabis flowers. They share a common biosynthetic origin: the plant produces CBGA, and enzymes convert it into the acidic precursors of the other major cannabinoids.

That single fact explains a lot about cannabis chemistry. CBGA is the branch point. How much goes down each pathway is genetically determined, which is why cultivars differ predictably in cannabinoid profile — and why genetics constrain what a plant can produce regardless of how it is grown.

The Acidic Forms Come First

This is the part most product labels obscure.

A living cannabis plant does not contain meaningful quantities of THC. It contains THCA — tetrahydrocannabinolic acid — which is not intoxicating. THCA converts to THC through decarboxylation, a reaction driven by heat and, more slowly, by time.

The same applies across the family: CBDA becomes CBD, CBGA becomes CBG, and so on. Smoking, vaporising or baking drives the conversion. Eating raw cannabis largely does not.

Laboratories measure both forms and report them separately, which is why a certificate lists THC and THCA as distinct lines. Total THC is then calculated to account for the conversion, using a factor derived from the difference in molecular weight — roughly 0.877.

Two things follow. First, total THC will not equal the THC line on the report; it is a calculated figure. Second, it assumes complete conversion, which real-world heating does not achieve. The reported total is a theoretical maximum rather than what a consumer actually receives. More in THC percentage explained.

The Major Cannabinoids

THC (delta-9-tetrahydrocannabinol)

The compound responsible for cannabis’s intoxicating effects, acting primarily at CB1 receptors concentrated in the central nervous system. It is the most studied cannabinoid and the one every regulatory framework is built around — the 0.3% delta-9 THC threshold is what legally separates hemp from marijuana.

CBD (cannabidiol)

Non-intoxicating, and the second most studied. CBD interacts with the endocannabinoid system differently from THC — it does not bind strongly to CB1 in the way THC does, and much of its activity involves other receptor systems entirely.

It is the only cannabinoid with an approved pharmaceutical formulation in the United States, for specific severe epilepsy syndromes. That approval is narrow and does not extend to the claims made across the retail CBD market.

CBG (cannabigerol)

The neutral form of the precursor from which the others derive. Because most CBGA is converted during growth, mature plants usually contain little CBG — which is why CBG-dominant cultivars are deliberately bred and why CBG products are more expensive.

CBN (cannabinol)

CBN is largely a degradation product. THC oxidises to CBN with exposure to heat, light and oxygen over time, so an elevated CBN figure alongside reduced THC generally indicates age or poor storage rather than genetics.

That makes CBN a useful data point on a certificate. It is an indirect read on how the material was handled — see how to store cannabis properly.

CBC (cannabichromene)

Present in small quantities in most cultivars, non-intoxicating, and considerably less studied than the compounds above.

Delta-8 and the Hemp-Derived Cannabinoids

Delta-8-THC is an isomer of delta-9 — the same atoms arranged slightly differently, with reportedly milder intoxicating effects.

It occurs naturally in trace amounts, far too little to extract economically. Commercial delta-8 is almost always produced by chemically converting CBD, which sits in a legal gray area created by the hemp threshold in the 2018 Farm Bill.

From a testing perspective the concern is straightforward: chemical conversion can leave reaction by-products and residual reagents that standard cannabis panels were not designed to detect. The same applies to other semi-synthetic hemp-derived cannabinoids that have appeared on the market. This is one of the gaps discussed in the limits of current testing methods.

How Laboratories Measure Them

Cannabinoid quantification is done by high-performance liquid chromatography. The choice of HPLC over gas chromatography is deliberate: gas chromatography introduces heat, which would decarboxylate the acidic cannabinoids during the analysis and report a composition the sample never had.

The process separates compounds in solution, detects each as it elutes, and quantifies against calibrated reference standards. Results are reported as a percentage by weight for flower and concentrates, and in milligrams per serving and per package for infused products. See potency testing and the testing process.

Reading a Cannabinoid Profile

A few habits make the profile more useful.

• Look at THC and THCA separately, not only at total THC. The ratio tells you something about the product’s state.
• Check CBN. Elevated CBN with depressed THC suggests age or heat exposure.
• Note which minors were quantified. A panel reporting only THC and CBD is a narrower analysis than one covering the full set.
• Check the basis. Potency reported on a dry-weight basis differs from as-received, and the two are not comparable.
• Do not read potency as quality. It is a concentration measurement, nothing more.

Cannabinoids Are Only Part of the Profile

Two products with identical cannabinoid figures can behave quite differently, and cannabinoid content alone does not explain that.

Terpenes — the volatile aromatic compounds that give cultivars their smell — vary independently of cannabinoid content and are the other half of a chemical profile. How they interact with cannabinoids is covered in terpenes and the entourage effect, and how all of it interacts with human physiology in the endocannabinoid system.

The post Cannabinoids Explained: THC, CBD and What a Lab Measures appeared first on TruMo Analytics.

That sequence matters. The system is not there for cannabis. Cannabis happens to produce compounds that resemble molecules the body already uses.

The Three Components

The endocannabinoid system has three parts: receptors, the compounds that activate them, and the enzymes that build and break down those compounds.

Receptors

CB1 receptors are concentrated in the central nervous system — brain and spinal cord — with the highest densities in regions governing memory, mood, motor control, appetite and pain perception. They are among the most abundant receptors of their type in the brain.

THC’s intoxicating effects come from binding at CB1, and the distribution of those receptors is why the effects present the way they do. Notably, the brainstem regions controlling respiration have very few CB1 receptors, which is the pharmacological reason cannabis does not suppress breathing the way opioids can.

CB2 receptors are found mainly in immune tissue and peripheral organs. Activity here relates more to immune signalling and inflammation than to psychoactive effect.

Cannabinoids also interact with other targets — TRPV1, GPR55, serotonin and PPAR receptors among them — which is part of why CBD, which binds weakly at CB1, still has measurable effects.

Endocannabinoids

The body produces its own cannabinoids. Two are well characterized.

Anandamide (from the Sanskrit ananda, “bliss”) was the first identified. It binds at CB1 with moderate affinity and is broken down quickly by the enzyme FAAH.

2-AG is present at considerably higher concentrations and is a full agonist at both CB1 and CB2.

The crucial difference between endocannabinoids and plant cannabinoids is timing. Endocannabinoids are synthesised on demand, act locally, and are degraded within minutes. They are not stored and released like conventional neurotransmitters — they are made where and when they are needed, then removed.

Enzymes

FAAH breaks down anandamide; MAGL breaks down 2-AG. These are pharmacological targets in their own right — inhibiting them raises endocannabinoid levels without introducing an external compound, which is an active line of drug development independent of cannabis.

What the System Does

The endocannabinoid system operates largely as a regulator rather than a driver. Its main mechanism is retrograde signalling: a receiving neuron produces endocannabinoids that travel backwards across the synapse and reduce further transmitter release from the sending neuron.

Functionally it is a dimmer switch. It participates in maintaining balance across appetite and metabolism, pain perception, mood and stress response, sleep, immune function, memory, and motor control.

Because it modulates so many systems, disrupting it produces wide-ranging effects — and because it is a regulator rather than a primary driver, its effects are usually adjustments rather than switches.

Anandamide and THC Compared

Both act at CB1, and the differences explain a great deal.

Duration. Anandamide is degraded within minutes. THC persists for hours and is stored in fat tissue, releasing slowly over a much longer period.

Location. Endocannabinoids act precisely where they are produced. Inhaled or ingested THC reaches CB1 receptors throughout the body at once — including regions where the body was not signalling for any change.

Intensity. Endocannabinoid signalling is calibrated. THC arrives at whatever concentration was consumed.

That combination — longer, broader, less calibrated — is why THC produces effects the body’s own system does not, despite acting at the same receptor.

Why CBD Behaves Differently

CBD does not bind strongly at CB1, which is why it is not intoxicating. Its activity appears to be indirect and distributed: modulating how the receptor responds to other compounds, affecting endocannabinoid breakdown, and acting at receptor systems outside the endocannabinoid system entirely.

This is also why CBD research is harder to interpret than THC research. A compound with several modest effects across multiple systems is more difficult to characterize than one with a strong effect at a single receptor. See the science behind medical cannabis research.

Why Effects Vary So Much Between People

Endocannabinoid systems differ between individuals — in receptor density and distribution, in enzyme activity, and in baseline endocannabinoid levels. Genetic variation in the FAAH gene, for instance, affects how quickly anandamide is broken down.

Regular THC exposure also downregulates CB1 receptors, which is the mechanism behind tolerance, and receptor density recovers with abstinence.

The practical implication is that no laboratory measurement predicts individual response. A certificate of analysis tells you precisely what is in a product; the endocannabinoid system on the receiving end is not something a laboratory can measure. This is the core reason potency is not a prediction — covered in THC percentage explained.

Where the Research Actually Stands

The endocannabinoid system is well established as a physiological system, and its role in regulating the functions above is not seriously disputed.

What is less settled is the therapeutic picture. The hypothesis of “clinical endocannabinoid deficiency” — that some conditions reflect an underactive endocannabinoid system — is a plausible framework that remains under-evidenced. Much of what is claimed for cannabinoid therapy rests on preclinical work rather than controlled human trials.

Understanding the system explains mechanism. It does not, on its own, establish clinical effect. That distinction is worth holding onto when reading cannabis health claims, and it is the framing behind conditions most often studied in medical cannabis research.

For what the plant actually produces, see cannabinoids explained and terpenes and the entourage effect.

The post The Endocannabinoid System and How Cannabis Interacts With It appeared first on TruMo Analytics.

What Terpenes Are

Terpenes are volatile aromatic compounds produced across the plant kingdom. They are what makes pine smell like pine and lemon peel smell like lemon, and they are produced in cannabis in the same trichomes that produce cannabinoids.

For the plant, they are functional rather than decorative: deterring herbivores, attracting pollinators, and offering some protection against fungal growth and UV exposure.

Cannabis produces well over a hundred, though a much smaller number appear at concentrations that meaningfully shape a profile. Because they are volatile, they are also fragile — heat, light, time and rough handling all degrade them, which is why old flower smells flat even when its cannabinoid figures remain reasonable.

The Ones That Show Up Most

Myrcene is frequently the most abundant terpene in cannabis. Earthy and herbal, also present in hops and mangoes. It is the compound behind the persistent claim that indica cultivars are more sedating — a claim discussed below and in indica, sativa and hybrid explained.

Limonene is citrus-forward and, unsurprisingly, abundant in citrus peel.

Caryophyllene is peppery and spicy, also found in black pepper and cloves. It is chemically unusual among terpenes in that it binds directly to CB2 receptors, which makes it the one terpene with an established direct interaction with the endocannabinoid system.

Pinene is the pine note, in both alpha and beta forms.

Linalool is floral, and the dominant terpene in lavender.

Terpinolene is a more complex profile — floral, herbal, slightly citrus — and appears at high levels in a relatively small set of cultivars.

Humulene is woody and earthy, the characteristic hop aroma.

Ocimene is sweet and herbaceous.

The Entourage Effect: What Is Actually Claimed

The entourage effect is the proposition that cannabis compounds act differently together than in isolation — that terpenes and minor cannabinoids modulate the effects of THC and CBD, so a whole-plant preparation behaves differently from an equivalent dose of isolated compounds.

It is worth separating what is reasonably established from what is asserted.

Reasonably established: some terpenes have documented biological activity in their own right, caryophyllene binds CB2 directly, CBD demonstrably modulates some effects of THC in controlled studies, and full-spectrum and isolate preparations at matched cannabinoid doses have shown different results in some research.

Asserted more confidently than the evidence supports: specific claims about which terpene produces which effect at the concentrations actually present in cannabis. The commercial narrative — myrcene sedates, limonene lifts mood, pinene improves focus — extends well beyond what controlled human trials have shown.

Most of the supporting work is preclinical, or uses terpene concentrations far above what cannabis contains. That does not make the hypothesis wrong. It means the confident version marketed at consumers is not yet backed by the evidence, and it is reasonable to say so.

Why the Indica/Sativa Explanation Does Not Hold Up

Terpene profiles have been widely used to rescue the indica/sativa distinction — the argument being that the categories map onto terpene chemistry even if they do not map onto genetics.

Chemical analysis across large numbers of samples has not supported this cleanly. Cultivars sold as indica and sativa do not separate reliably by terpene profile, and the same cultivar name frequently carries substantially different chemistry between producers.

What terpene data does support is chemotype-based classification — grouping products by measured chemical profile rather than by inherited category labels. That is a genuinely more useful framework, and it depends entirely on the analysis being run. See indica, sativa and hybrid.

How Terpenes Are Measured

Because terpenes are volatile, gas chromatography is the appropriate technique, usually with mass spectrometry for identification. Sample preparation matters more than for cannabinoid analysis — terpenes can be lost during handling, and a method that loses them reports a profile that is accurate about what reached the instrument and wrong about the product.

Terpene analysis is optional under most compliance frameworks, which is why plenty of certificates omit it. Commercially that is changing: dispensary buyers increasingly ask for terpene data, and cultivators who can supply a detailed chemotype alongside potency figures have something to differentiate on in a market where potency alone no longer does.

What Terpene Data Is Actually Good For

Setting aside the effect claims, terpene analysis has concrete uses.

Consistency tracking. A terpene profile is a chemical fingerprint. Comparing it across harvests shows whether a cultivar is being reproduced consistently — something potency figures alone will not reveal.

Process feedback. Terpene loss between harvest and testing indicates problems in drying, curing or storage. Aggressive drying strips terpenes, and the data shows it.

Cultivar verification. Where the same name carries different chemistry between producers, the profile is a more reliable identifier than the label.

Personal reference. For consumers, tracking which measured profiles you respond well to is more useful than tracking cultivar names, because the names are not consistent and the chemistry is.

Preserving Them

Terpenes degrade faster than cannabinoids, and the same conditions that protect one protect the other: cool, dark, sealed, with stable humidity. Heat is the fastest way to lose them.

This is also why extraction method affects terpene content substantially. Processes involving heat and vacuum strip volatile compounds, which is why some producers reintroduce terpenes after extraction — a practice worth knowing about when reading a concentrate’s profile, since reintroduced terpenes may not be cannabis-derived.

Storage is covered in how to store cannabis properly, and the cannabinoid side of the profile in cannabinoids explained.

The post Terpenes and the Entourage Effect appeared first on TruMo Analytics.

This is worth understanding, because the indica vs sativa vs hybrid framework is probably the single most common way consumers make purchasing decisions — and it is not doing what people think it is doing.

Where the Categories Came From

The distinction originated in eighteenth-century botany. Cannabis sativa was described by Linnaeus in 1753 from European hemp. Cannabis indica was described by Lamarck in 1785 from Indian material, which differed in appearance and in psychoactive potency.

The names described plant morphology — height, leaf shape, branching pattern, flowering time — in geographically separated populations. They were never intended to describe effects on humans, and they did not.

The modern usage arrived through cannabis breeding culture in the twentieth century, where the terms drifted from describing plant structure to predicting experience: indica as sedating and physical, sativa as energising and cerebral.

Why It Does Not Hold Up

Three problems, each sufficient on its own.

Nearly everything is a hybrid. Decades of intensive breeding, much of it undocumented and conducted under prohibition, have thoroughly mixed the gene pools. Genetic analysis of commercial cultivars consistently finds that products labeled indica and sativa do not separate into distinct genetic groups. The categories describe an ancestry that no longer exists in any pure form.

The labels do not predict chemistry. Chemical analysis across large sample sets has repeatedly found that indica and sativa labeling does not correlate reliably with cannabinoid or terpene profile. Two products labeled indica can be chemically further apart than one indica and one sativa.

Names are not standardized. There is no registry governing cultivar names. The same name from two producers can be genetically and chemically different material, and there is no authority to appeal to. Genetic verification regularly finds that identically named products from different sources are not the same plant. See cannabis strains and the genetics behind them.

The Myrcene Argument

The most common defense is that indica cultivars are higher in myrcene, and that myrcene above a certain threshold produces sedation.

Two problems. Myrcene content does not track the indica/sativa label consistently across large samples. And the sedation threshold that circulates widely in cannabis marketing does not trace back to a controlled human trial — it is a figure that has been repeated until it acquired the appearance of evidence.

Terpenes are genuinely interesting and genuinely worth measuring. The confident effect claims attached to them run ahead of the research, which is covered honestly in terpenes and the entourage effect.

Why It Persists Anyway

Because it is useful as a communication shorthand, even though it is inaccurate as chemistry.

A customer who says they want “an indica” is usually communicating something real: they want something relaxing, for the evening, not stimulating. A budtender who hears that can make a reasonable recommendation. The category is functioning as a proxy for an intention, and the recommendation may well work.

The problem is that it works unreliably, and it fails silently. When a product labeled indica produces an unexpected effect, the framework offers no explanation — because the label was never carrying the information the customer assumed it was.

What Actually Predicts the Experience

Several things, none of which appear in the indica/sativa label.

The measured cannabinoid profile. Total THC, the THC:CBD ratio, and which minor cannabinoids are present at what levels. A high-THC, low-CBD product behaves differently from a balanced one regardless of category. See cannabinoids explained.

The measured terpene profile. The actual chemistry, not the inherited label.

Route of administration. Inhalation reaches peak effect within minutes and resolves in a few hours. Ingestion takes considerably longer to onset, lasts far longer, and involves different metabolism. This difference is larger than any difference between cultivars — covered in forms of medical cannabis.

Dose. The same product at different doses produces different effects, sometimes in opposite directions.

The individual. Tolerance, physiology, endocannabinoid system variation, expectation and setting. Two people consuming identical material from the same jar can have entirely different experiences — see the endocannabinoid system.

The Better Framework: Chemotypes

Researchers and an increasing number of producers use chemovar or chemotype classification — grouping products by measured chemical profile rather than by inherited category.

A chemotype description looks like: total THC 22%, CBD below 1%, dominant terpenes limonene and caryophyllene. That describes the product. “Sativa-dominant hybrid” does not.

The obstacle is not conceptual. It is that chemotype classification requires the analysis to have been run and the data to be published — which means terpene analysis alongside potency, and a certificate that reaches the customer.

Practical Advice

For consumers: use the category as a rough starting point if you like, but treat the certificate of analysis as the actual information. Track which measured profiles you respond well to rather than which names — names are not consistent, chemistry is. How to check a product properly is in choosing tested cannabis products.

For producers: full chemical profiles are increasingly a differentiator. In a market where potency competition has run its course, a documented chemotype is something to compete on — and it is more defensible than a category label anyone can apply to anything.

The post Indica, Sativa and Hybrid: What the Labels Actually Mean appeared first on TruMo Analytics.

Understanding how cannabis genetics actually work makes the market considerably easier to read.

What a Cultivar Is

“Strain” is the term the industry uses; “cultivar” — cultivated variety — is the correct horticultural word, and the distinction is more than pedantry.

A cultivar is a plant population selected and maintained for particular characteristics. In cannabis those characteristics might be cannabinoid profile, terpene profile, yield, flowering time, structure, or resistance to mold and pests.

Crucially, cannabis is not genetically uniform the way many agricultural crops are. It is dioecious and outcrossing, which means seeds from the same cross vary. Two plants from one seed packet can differ noticeably — a fact with practical consequences for everything downstream.

How New Cultivars Are Made

Crossing

The basic method: pollinate a female plant with pollen from a selected male, grow out the resulting seeds, and evaluate.

The complication is that males show no flowers to assess. A breeder selecting a male is selecting on structure, vigour, and — increasingly — genetic testing, since the male contributes half the genetics and cannot be judged on the traits that matter most.

Phenotype hunting

Grow out a large number of seeds from a cross, evaluate every plant, and select the individuals expressing the desired combination.

This is where most commercial cultivars actually come from. A breeder might grow hundreds of seeds and keep one or two. Those selections are then maintained as clones — genetically identical copies — because seed propagation would reintroduce variation.

Almost every named cultivar in commercial production is a clone line descended from a single selected plant.

Backcrossing

Crossing offspring back to a parent to concentrate a specific trait. Slower, more deliberate, and how stable characteristics get fixed.

Tissue culture

Propagating from small amounts of plant tissue in sterile conditions. It preserves genetics without the pathogen accumulation that affects long-running clone lines, and it allows storage of genetics without maintaining live mother plants.

This matters more than it sounds. Clone lines degrade — viroids and pathogens accumulate over generations, and a cultivar that performed well five years ago may not now. Hop latent viroid in particular has caused significant losses across the industry, often undiagnosed and mistaken for poor growing.

What Genetics Determines, and What It Does Not

Genetics sets the boundaries. Environment determines where inside them a plant lands.

Genetics governs which cannabinoids a plant can produce and in roughly what ratio, which terpenes it can produce, structure and growth habit, flowering time, and disease resistance.

Environment governs how much of that potential is realised: light intensity and spectrum, temperature, humidity, nutrition, growing medium, harvest timing, and — heavily — drying and curing.

The practical consequence is that the same clone grown in two facilities produces measurably different results. Identical genetics do not mean identical product, which is why testing every batch is not redundant even when the cultivar is well characterized.

The Naming Problem

There is no registry of cannabis cultivar names, no authority verifying claims, and no consequence for using a name that does not correspond to the genetics.

This produces exactly what you would expect. The same name from different producers is frequently different material. Popular names get applied to unrelated genetics for marketing reasons. Renamed cultivars circulate as new releases. And genuinely distinct cultivars are impossible to distinguish from renamed ones on the label alone.

Genetic testing regularly confirms this. Studies comparing identically named samples from different sources have found substantial genetic divergence — sometimes more than between differently named samples.

The practical read: the name on the jar is branding. The certificate of analysis is information. Which is the same conclusion reached in indica, sativa and hybrid explained.

Where Genetic Testing Comes In

Sequencing has moved from research into commercial use, and it addresses several real problems.

Verification. Confirming that two samples are genetically the same plant — useful for protecting a cultivar line and for checking what you actually bought.

Sex determination. Identifying plant sex at seedling stage rather than at flowering saves considerable time and space.

Pathogen screening. Detecting viroids and pathogens in mother plants before they spread through a clone line.

Marker-assisted selection. Screening seedlings for genetic markers associated with desired traits, rather than growing everything to maturity to find out.

What genetics cannot do is replace chemical analysis. It tells you what a plant is capable of producing. Only testing the finished material tells you what it actually produced under the conditions it was grown in. More on the instrumentation in cannabis testing technology.

Where Breeding Is Going

Several directions look durable.

Minor cannabinoids. CBG-dominant and CBN-forward cultivars, and work on rarer cannabinoids, driven by interest in profiles beyond THC and CBD.

Terpene-led selection. Breeding for specific aromatic profiles rather than for potency alone, as the market shifts away from THC percentage as the sole differentiator.

Disease resistance. Increasingly urgent given how much production is lost to mold and viroids, and directly relevant to microbial test results.

Environmental efficiency. Cultivars that perform in lower-input conditions, connecting to the sustainability pressures in sustainable cannabis cultivation.

Whether any of this produces reliable consumer-facing differentiation depends on something other than breeding: whether the chemistry is measured and published. Genetics without analysis is a claim.

The post New Cannabis Strains and the Genetics Behind Them appeared first on TruMo Analytics.

Long use is not evidence of efficacy — plenty of long-used remedies did not survive controlled testing. What matters is what has been demonstrated, and understanding medical cannabis science means understanding why some of it is solid, much of it is preliminary, and the two are constantly conflated.

Why Cannabis Research Is Genuinely Difficult

Schedule I status. In the United States, cannabis’s classification has made research administratively burdensome for decades — special licensing, restricted supply, and until recently a single federally approved source whose material was not representative of what patients actually use. Researchers have spent years on approvals that would take weeks for other compounds.

Blinding is hard. A double-blind trial requires participants not to know whether they received the treatment. THC is intoxicating, so most participants can tell. That compromises blinding and inflates placebo-attributable effects in ways that are difficult to correct for. CBD trials are easier to blind, which is one reason CBD evidence is generally cleaner.

The intervention is not standardized. “Cannabis” describes a plant with variable composition, delivered by routes with very different pharmacokinetics, at doses that are frequently estimated. Two studies of “cannabis for pain” may have tested materially different interventions — which is why apparently contradictory results are often not contradictory at all.

This is precisely why laboratory characterisation of investigational material matters so much, as covered in how laboratory data supports research.

Whole plant versus isolated compounds. Pharmaceutical research is built around single, well-characterized molecules. A plant containing dozens of active compounds in variable ratios does not fit that framework easily, and the entourage hypothesis — that the compounds interact — makes isolating any one of them potentially misleading. See terpenes and the entourage effect.

How to Read the Evidence Hierarchy

Not all studies carry the same weight, and a great deal of cannabis reporting ignores this entirely.

• Systematic reviews and meta-analyses synthesise multiple trials. Strongest, when the underlying trials are good.
• Randomised controlled trials compare treatment against placebo or an alternative with random allocation. The standard for establishing efficacy.
• Observational studies follow people using cannabis without assigning treatment. Useful for real-world patterns; cannot establish causation.
• Case series and case reports describe individual outcomes. Hypothesis-generating, not evidence of effect.
• Preclinical studies — cell cultures and animal models — establish mechanism. Most preclinical findings do not translate to human clinical benefit.

The recurring failure in cannabis coverage is preclinical work reported as though it were clinical. “Cannabinoids kill cancer cells” almost invariably refers to cells in a dish, where a great many substances kill cancer cells — including substances that would kill the patient.

Where the Evidence Is Strongest

A few areas have accumulated substantial support.

Chemotherapy-induced nausea and vomiting. Among the best-established indications, with synthetic cannabinoid medications approved on this basis for decades.

Specific severe epilepsy syndromes. A purified CBD formulation has regulatory approval for Lennox-Gastaut and Dravet syndromes, supported by randomised controlled trials. This is the clearest example of cannabis-derived medicine meeting the pharmaceutical evidence standard.

Chronic pain. The most extensively studied indication. Reviews generally find modest benefit for some pain types — the effect is real and it is smaller than commonly claimed.

Multiple sclerosis spasticity. A standardized THC:CBD oromucosal spray is approved in several countries on trial evidence.

Where It Is Weaker

Many widely promoted applications rest on preclinical work, small trials, or observational data.

Anxiety research is mixed and dose-dependent, with evidence that higher THC doses can worsen anxiety. Sleep findings are inconsistent, and long-term effects on sleep architecture are not well characterized. Depression evidence is limited. Inflammatory conditions have promising mechanistic work and sparse clinical support. Neurodegenerative disease research is early. Cancer treatment claims are almost entirely preclinical, though cannabis’s role in managing treatment side effects is better supported.

Weak evidence is not evidence of absence — it means the question has not been answered adequately. That distinction matters in both directions, and it is the framing used throughout conditions most often studied in medical cannabis research.

Risks Are Part of the Science

Balanced reading includes what research shows about harms.

The association between high-potency cannabis use and psychosis risk, particularly in adolescence and in people with family history, is one of the more consistent findings in the literature. Cannabis use disorder affects a meaningful minority of regular users. Cannabinoid hyperemesis syndrome is well documented in heavy long-term users. Cognitive effects during intoxication are established, and questions about heavy adolescent use remain open. Cannabinoids also affect drug metabolism — see cannabis and drug interactions.

A source presenting only benefits is not summarising the research. It is selling something.

Reading a Study Before Repeating It

• Human or animal? The single most useful filter.
• How many participants? A dozen people is a pilot, not a finding.
• Was there a control group? Without one, you cannot separate the treatment from everything else.
• What exactly was administered? Composition, dose and route. If unstated, the study is difficult to interpret or replicate.
• What was measured? A change on a self-report scale is not the same as a change in a clinical outcome.
• How large was the effect? Statistical significance and clinical significance are different things.
• Who funded it, and has it been replicated? Single studies are starting points.

Where This Leaves Things

Medical cannabis is neither the panacea of the advocacy literature nor the empty claim of the skeptical one. It has demonstrated benefit for a small number of conditions, plausible but unproven benefit for many more, and real risks that vary by dose, potency, frequency and individual.

The evidence base is improving as research restrictions ease and material is better characterized. Both halves matter — you cannot run good trials on an intervention nobody has measured. That is the connection between analytical testing and clinical knowledge, and it is covered in what cannabis lab testing is.

The post The Science Behind Medical Cannabis Research appeared first on TruMo Analytics.